- Home
- TNYA vs MGNX Comparison
TNYA vs MGNX Comparison
Compare TNYA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- MGNX
- Stock Information
- Founded
- TNYA 2016
- MGNX 2000
- Country
- TNYA United States
- MGNX United States
- Employees
- TNYA N/A
- MGNX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- MGNX Health Care
- Exchange
- TNYA Nasdaq
- MGNX Nasdaq
- Market Cap
- TNYA 73.8M
- MGNX 87.7M
- IPO Year
- TNYA 2021
- MGNX 2013
- Fundamental
- Price
- TNYA $0.63
- MGNX $1.24
- Analyst Decision
- TNYA Strong Buy
- MGNX Hold
- Analyst Count
- TNYA 5
- MGNX 9
- Target Price
- TNYA $8.60
- MGNX $5.33
- AVG Volume (30 Days)
- TNYA 3.0M
- MGNX 2.6M
- Earning Date
- TNYA 08-07-2025
- MGNX 08-05-2025
- Dividend Yield
- TNYA N/A
- MGNX N/A
- EPS Growth
- TNYA N/A
- MGNX N/A
- EPS
- TNYA N/A
- MGNX N/A
- Revenue
- TNYA N/A
- MGNX $154,050,000.00
- Revenue This Year
- TNYA N/A
- MGNX N/A
- Revenue Next Year
- TNYA N/A
- MGNX N/A
- P/E Ratio
- TNYA N/A
- MGNX N/A
- Revenue Growth
- TNYA N/A
- MGNX 255.31
- 52 Week Low
- TNYA $0.36
- MGNX $0.99
- 52 Week High
- TNYA $4.06
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- TNYA 53.87
- MGNX 38.61
- Support Level
- TNYA $0.54
- MGNX $1.26
- Resistance Level
- TNYA $0.70
- MGNX $1.41
- Average True Range (ATR)
- TNYA 0.06
- MGNX 0.17
- MACD
- TNYA 0.00
- MGNX -0.03
- Stochastic Oscillator
- TNYA 34.57
- MGNX 1.10
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.